Blair R Leavitt

发表

Depletion of wild‐type huntingtin in mouse models of neurologic diseases

Martin Drozda, Mingwei Li, Elena Cattaneo, 2003, Journal of neurochemistry.

A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration

Claire-Anne Gutekunst, Xiao-Jiang Li, Steven M Hersch, 1999, Neuron.

Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease

Carlos Cepeda, Michael S Levine, C. Cepeda, 2009, The Journal of Neuroscience.

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

Andrea Crotti, Elena Cattaneo, M. Hayden, 2003, Nature Genetics.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Merit Cudkowicz, Shiyang Ma, E Ray Dorsey, 2017, Neurology.

Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease

Yu Deng, Ge Lu, Robert Friedlander, 2009, The Journal of Neuroscience.

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease

M. Hayden, B. Leavitt, G. Johnson, 2005, Journal of neurochemistry.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Enrico Amico, Philippe Allain, Mark Mühlau, 2017, The Lancet. Neurology.

Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.

M. Hayden, B. Leavitt, E. Slow, 2005, Human molecular genetics.

Iron dysregulation in Huntington's disease

B. Leavitt, Blair R Leavitt, Michelle Muller, 2014, Journal of neurochemistry.

Large‐scale brain network abnormalities in Huntington's disease revealed by structural covariance

Stefan Klöppel, Simon B Eickhoff, Ahmed Abdulkadir, 2016, Human brain mapping.

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease

M. Hayden, B. Leavitt, J. Pearson, 2006, BMC Neuroscience.

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

Chris Frost, Alexandra Durr, Ralf Reilmann, 2013, The Lancet Neurology.

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

Mauro Delorenzi, Thierry Sengstag, Darlene R Goldstein, 2007, Human molecular genetics.

Forkhead box protein p 1 is a transcriptional repressor of immune signaling in the CNS : implications for transcriptional dysregulation in Huntington disease

Brian Spencer, E. Masliah, B. Leavitt, 2012 .

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

Chris Frost, Nick C Fox, Christopher Kennard, 2011, The Lancet Neurology.